title: Pharmacological and pharmacokinetic studies with vitamin D-loaded nanoemulsions in asthma model.
abstract: Vitamin D (VD) was studied for its anti-inflammatory activities with prepared VD-loaded nanoemulsions (VDNM) in ovalbumin-induced asthmatic mice in this paper. In this study, we prepared VDNM for the delivery of VD from the established composition of solid self-emulsifying drug delivery systems (sSEDDS) by spray-drying technique and evaluated its bioavailability (BA) and anti-inflammatory activities in experimental allergic asthma. After the mice were treated orally with VD or VDNM, the plasma 25(OH) D levels, polymorphonuclear cells, tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), total antioxidant activity, and C3 and C4 complement protein levels were studied, respectively. Treatment with VDNM reduced MPO activity, oxidative stress, C3 protein level, O2(-) level as well as the production of IL-1β and TNF-α. Pharmacokinetic studies showed that a significant increase in the maximum concentration (Cmax) and AUC0→24 h were observed in VDNM group when compared with VD group (P < 0.01). The result revealed that VDNM led to an improvement in oral BA of VD in a murine ovalbumin-induced asthma model. These data provided an important proof that VDNM might be a new potential therapy for the management of asthma in humans.
authors: Taizhou Enze Medical Center Luqiao Hospital, Zhejiang, 318050, People's Republic of China.
authors: Tang
authors: T
authors: Wei-hong
authors: Guan
authors: G
authors: Min-chang
authors: Xu
authors: X
authors: Zhen
authors: Sun
authors: S
authors: Jie
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D003176:Complement C3 / Q000096:biosynthesis; D003181:Complement C4 / Q000096:biosynthesis; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000494:pharmacology; D004655:Emulsions / Q000494:pharmacology; D005260:Female; D018836:Inflammation Mediators / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D053761:Nanocomposites; D009504:Neutrophils / Q000276:immunology; D010047:Ovalbumin; D018384:Oxidative Stress / Q000187:drug effects; D011897:Random Allocation; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014807:Vitamin D / Q000097:blood* / Q000494:pharmacology*
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; C016759:C4b protein, mouse; D003176:Complement C3; D003181:Complement C4; D004337:Drug Carriers; D004655:Emulsions; C587672:IL1B protein, mouse; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D014807:Vitamin D; D010047:Ovalbumin